E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
Farhad Ravandi,Jeffrey L. Jorgensen,Susan O'Brien,Elias Jabbour,Deborah A. Thomas,Gautam Borthakur,Rebecca Garris,Xuelin Huang,Guillermo Garcia-Manero,Jan A. Burger,Alessandra Ferrajoli,William G. Wierda,Tapan M. Kadia,Nitin Jain,Sa A. Wang,Sergei Konoplev,Partow Kebriaei,Richard E. Champlin,Deborah McCue,Zeev Estrov,Jorge E. Cortes,Hagop M. Kantarjian +21 more
TL;DR: Investigation of the prognostic value of minimal residual disease assessed by multi‐parameter flow cytometry among 340 adult patients with B‐cell acute lymphoblastic leukaemia treated between 2004 and 2014 indicated that MRD negative status at CR was an independent predictor of DFS and OS.
Journal ArticleDOI
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen
Michael Rytting,Elias Jabbour,Jeffrey L. Jorgensen,Farhad Ravandi,Anna Franklin,Tapan M. Kadia,Naveen Pemmaraju,Naval Daver,Alessandra Ferrajoli,Guillermo Garcia-Manero,Marina Konopleva,Gautam Borthakur,Rebecca Garris,Sa Wang,Sherry Pierce,Kurt Schroeder,Steven M. Kornblau,Deborah A. Thomas,Jorge E. Cortes,Susan O'Brien,Hagop M. Kantarjian +20 more
TL;DR: ABFM and hyper‐CVAD resulted in similar efficacy outcomes, but were associated with different toxicity profiles, asparaginase‐ related with ABFM and myelosuppression‐related with hyper‐ CVAD.
Journal ArticleDOI
Recommendations for the Assessment and Management of Measurable Residual Disease in Adults With Acute Lymphoblastic Leukemia: A Consensus of North American Experts
Nicholas J. Short,Elias Jabbour,Maher Albitar,Marcos de Lima,Lia Gore,Jeffrey L. Jorgensen,Aaron C Logan,Jae H. Park,Farhad Ravandi,Bijal D. Shah,Jerald P. Radich,Hagop M. Kantarjian +11 more
TL;DR: The role of MRD assessment in adults with ALL is reviewed, including methods to quantify residual leukemia cells during remission, prognostic impact of MRd across ALL subtypes, and available therapeutic approaches to eradicate MRD are reviewed.
Journal ArticleDOI
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.
Kiran Naqvi,Elias Jabbour,Carlos E. Bueso-Ramos,Sherry Pierce,Gautam Borthakur,Zeev Estrov,Farhad Ravandi,Stefan Faderl,Hagop M. Kantarjian,Guillermo Garcia-Manero +9 more
TL;DR: Patients referred to tertiary care centers occasionally may have their diagnostic procedures repeated and have a final diagnosis that differs from that of the referring center, demonstrating the complexity of the diagnosis of MDS.
Journal ArticleDOI
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.
Maro Ohanian,Guillermo Garcia-Manero,Mark J. Levis,Elias Jabbour,Naval Daver,Gautam Borthakur,Tapan M. Kadia,Sherry Pierce,Jan A. Burger,Mary Ann Richie,Keyur P. Patel,Michael Andreeff,Zeev Estrov,Jorge E. Cortes,Hagop M. Kantarjian,Farhad Ravandi +15 more
TL;DR: The combination of sorafenib with 5‐azacytidine (AZA) in relapsed/refractory patients with FLT3 mutated acute myeloid leukemia (AML) was efficacious and well tolerated in untreated patients who are unsuitable for standard chemotherapy due to advanced age or lack of fitness.